Skip to main content
Profound Medical Corp. logo

Profound Medical Corp. — Investor Relations & Filings

Ticker · PROF TSX Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2020-07-15 Capital/Financing Update
Country CA Canada
Listing TSX PROF

About Profound Medical Corp.

https://profoundmedical.com/

Profound Medical Corp. is a commercial-stage medical technology company specializing in incision-free ablative therapies. Its core product is TULSA-PRO®, a therapeutic platform designed for the treatment of localized prostate cancer, radiorecurrent prostate cancer, and benign prostatic hyperplasia (BPH). TULSA-PRO utilizes a robotically controlled, transurethral ultrasound ablation procedure guided by real-time Magnetic Resonance (MR) imaging. This system employs closed-loop temperature feedback to ensure precise and customizable tissue ablation, prioritizing patient safety and minimizing complications. The technology merges MR imaging, thermal ultrasound, and robotics to offer a durable and accurate treatment delivery method.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a proposed offering of common shares by Profound Medical Corp. It discusses the intention to file a preliminary prospectus supplement and provides details about the offering, underwriters, use of proceeds, and regulatory filings related to the offering. There are no financial statements or detailed financial performance data included. The document is primarily an announcement of a capital raising activity, specifically a public offering of shares. This fits the category of Capital/Financing Update (CAP). The document length is 8210 characters, which is sufficient for a detailed announcement but does not contain the actual prospectus or financial report itself, only the announcement of the offering and related information.
2020-07-15 English
Other.pdf
Investor Presentation Classification · 95% confidence The document is titled 'Corporate Presentation | July 15, 2020 – Offering of Common Shares' and contains forward-looking statements, market and industry data, COVID-19 impact discussion, and product information. It references a shelf prospectus and SEC filings related to a securities offering. The content is typical of an investor presentation focusing on company strategy, market opportunity, product overview, and financing context. There are no detailed financial statements or audit information, nor is it a regulatory filing or earnings release. The document is not a report publication announcement since it contains substantive presentation content rather than just announcing a report. Therefore, the document fits best into the 'Investor Presentation' category (IP).
2020-07-15 English
Draft shelf prospectus supplement – English.pdf
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement related to a short form base shelf prospectus for the offering of common shares by Profound Medical Corp. It details the terms of the offering, underwriting agreement, pricing, and regulatory disclaimers. This type of document is a capital raising filing that provides information about a new share issuance and the associated underwriting. It is not an annual report, earnings release, or management discussion. It is clearly a financing update related to a new share offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or a brief summary.
2020-07-15 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Report of Voting Results Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations' and details the voting outcomes at the annual and special meeting of shareholders held on May 20, 2020. It includes specific vote counts and percentages for appointment of auditors, election of directors, and approval of a long-term incentive plan. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at any general meeting. The document length is short (2256 characters) and it is not a full report but a voting result announcement. Therefore, the correct classification is DVA with high confidence.
2020-05-20 English
News release - English.pdf
Regulatory Filings
2020-05-20 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the Chief Financial Officer regarding the interim financial report and interim MD&A for the period ended March 31, 2020. It references National Instrument 52-109, which relates to certification of disclosure in issuers' annual and interim filings. The document does not contain actual financial data or substantive financial analysis but is a formal attestation of the accuracy and fairness of the interim filings. The document length is 3350 characters, which is relatively short and consistent with a certification letter rather than a full interim report. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR).
2020-05-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.